# waveLINE-007 (NCT05406401)

> A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05406401
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Lymphoma, Large B-Cell, Diffuse (DLBCL)
- Interventions: Zilovertamab Vedotin; Cyclophosphamide; Doxorubicin; Rituximab; Rituximab Biosimilar; Prednisone; Prednisolone
- Enrollment: 60
- Primary outcome: Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) in Cycle 1
- Primary outcome: Number of Participants Who Experienced At Least One AE
- Primary outcome: Number of Participants Who Discontinued Study Treatment Due to an AE
- Primary outcome: Complete Response Rate (CRR) per Lugano Response Criteria

## Commentary we found

- YouTube: 4
- Podcasts: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=waveline-007-nct05406401